Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.
- Conditions
- Interventions
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 93
- Registration Number
- NCT06372626
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
The Impact of Neoadjuvant Chemotherapy on Survival Outcomes in Patients With Variant Histologies Bladder Cancer Who Underwent Radical Cystectomy
- Conditions
- Interventions
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Ankara Etlik City Hospital
- Target Recruit Count
- 221
- Registration Number
- NCT06358599
- Locations
- 🇹🇷
Ankara Etlik City Hospital, Ankara, Turkey
A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 460
- Registration Number
- NCT06333821
Hypofractionated Radiochemotherapy
- Conditions
- Interventions
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Denise Fabian
- Target Recruit Count
- 20
- Registration Number
- NCT06331468
- Locations
- 🇺🇸
Markey Cancer Center, Lexington, Kentucky, United States
Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 39
- Registration Number
- NCT06331845
SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-03-21
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 148
- Registration Number
- NCT06323239
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-03-21
- Last Posted Date
- 2024-03-21
- Target Recruit Count
- 45
- Registration Number
- NCT06323460
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 780
- Registration Number
- NCT06312137
- Locations
- 🇨🇳
Zhongshan Hospital of Fudan University ( Site 1325), Shangai, Shanghai, China
🇫🇷Groupe hospitalier Paris saint Joseph. ( Site 1807), Paris, Ile-de-France, France
🇫🇷Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne-ONCOLOGY ( Site 1810), Clermont-Ferrand, Puy-de-Dome, France
GAMEC-II, Risk-adapted Protocol for Relapsed Germ Cell Tumours (GCT)
- Conditions
- Interventions
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 36
- Registration Number
- NCT06309732
- Locations
- 🇬🇧
Barts and the London NHS Trust, London, United Kingdom
The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients.
- Conditions
- Interventions
- First Posted Date
- 2024-03-06
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Odense University Hospital
- Target Recruit Count
- 264
- Registration Number
- NCT06295094
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇫🇷University Hospital Lille, Lille, France
🇩🇪Charité, University of Berlin, Berlin, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.